Automate Your Wheel Strategy on AMGN
With Tiblio's Option Bot, you can configure your own wheel strategy including AMGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AMGN
- Rev/Share 68.1614
- Book/Share 16.0631
- PB 21.0788
- Debt/Equity 6.3068
- CurrentRatio 1.14
- ROIC 0.1118
- MktCap 182324170394.0
- FreeCF/Share 15.0278
- PFCF 22.5092
- PE 23.6675
- Debt/Assets 0.6028
- DivYield 0.0281
- ROE 0.9665
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | AMGN | Bernstein | Outperform | Market Perform | -- | $335 | Jan. 20, 2026 |
| Resumed | AMGN | UBS | -- | Buy | -- | $380 | Jan. 7, 2026 |
| Upgrade | AMGN | Erste Group | Hold | Buy | -- | -- | Dec. 5, 2025 |
| Resumed | AMGN | Truist | -- | Hold | -- | $318 | Nov. 24, 2025 |
| Initiation | AMGN | Scotiabank | -- | Sector Outperform | -- | $385 | Nov. 13, 2025 |
| Resumed | AMGN | Raymond James | -- | Market Perform | -- | -- | Sept. 3, 2025 |
| Resumed | AMGN | Guggenheim | -- | Neutral | -- | $288 | May 20, 2025 |
| Resumed | AMGN | Cantor Fitzgerald | -- | Neutral | -- | $305 | April 22, 2025 |
| Resumed | AMGN | BofA Securities | -- | Underperform | -- | $256 | Dec. 10, 2024 |
| Initiation | AMGN | Bernstein | -- | Outperform | -- | $380 | Oct. 17, 2024 |
News
Amgen (AMGN) Stock Hits 52-Week Highs: Buy Signal?
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Neutral
Amgen ( AMGN ) is having a moment. The biotech bellwether is trading near fresh 52-week highs, up roughly 8% in the latest session, and the tape is sending a clear message: institutions are leaning in.
Read More
AMGN's Q4 Earnings & Sales Beat Estimates, Obesity Candidate in Focus
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Positive
Amgen delivers Q4 earnings and revenue beat, driven by strong drug volumes, as attention turns to its late-stage MariTide obesity studies.
Read More
Why Amgen Stock Is Paying Off Big For Long-Term Investors
Published: February 04, 2026 by: Forbes
Sentiment: Positive
Amgen's (AMGN) decade-long commitment to shareholder value is underscored by a staggering $86 billion capital return program, a feat that firmly establishes the biotech giant as a premier player in the global market.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
Amgen (AMGN) is a Top-Ranked Value Stock: Should You Buy?
Published: January 29, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Countdown to Amgen (AMGN) Q4 Earnings: Wall Street Forecasts for Key Metrics
Published: January 29, 2026 by: Zacks Investment Research
Sentiment: Neutral
Get a deeper insight into the potential performance of Amgen (AMGN) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Read More
Amgen Set to Report Q4 Earnings: What Investors Should Know
Published: January 28, 2026 by: Zacks Investment Research
Sentiment: Negative
AMGN stock is in focus ahead of Q4 earnings, with biosimilar pressure and newer drug growth shaping expectations for the quarter.
Read More
Analysts Estimate Amgen (AMGN) to Report a Decline in Earnings: What to Look Out for
Published: January 27, 2026 by: Zacks Investment Research
Sentiment: Negative
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Here's Why Amgen (AMGN) is a Strong Momentum Stock
Published: January 26, 2026 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
Published: January 23, 2026 by: Zacks Investment Research
Sentiment: Positive
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Amgen: A Buy In 2026 On Exciting MariTide Obesity - T2D Potential
Published: January 22, 2026 by: Seeking Alpha
Sentiment: Positive
Amgen Inc. is rated a Buy, driven by robust pipeline prospects and the transformative potential of its obesity drug candidate MariTide. Recent AMGN performance includes 12% revenue growth in Q3 2025, upwardly revised 2025 guidance, and healthy operating margins near 30%. Patent expiries will pressure legacy products, but new launches and biosimilars are expected to offset declines, with pipeline assets potentially accelerating growth post-2026.
Read More
Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses
Published: January 14, 2026 by: Benzinga
Sentiment: Positive
At a J.P. Morgan Healthcare Conference on Monday, Amgen Inc. (NASDAQ: AMGN) CEO Robert Bradway shared findings from part 2 of the Phase 2 Study of MariTide, its investigational obesity treatment.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: January 13, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Published: January 12, 2026 by: Zacks Investment Research
Sentiment: Positive
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Healthy Returns: What to expect from pharma at the JPM conference
Published: January 09, 2026 by: CNBC
Sentiment: Positive
At the JPMorgan Healthcare Conference, drugmakers are expected to roll out key business and drug pipeline updates and splashy M&A deals.
Read More
Amgen Buys Dark Blue Therapeutics to Strengthen Oncology Pipeline
Published: January 07, 2026 by: Zacks Investment Research
Sentiment: Positive
AMGN's $840M buyout of Dark Blue Therapeutics adds a preclinical AML degrader, bolstering its oncology pipeline.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Read More
AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE
Published: January 06, 2026 by: PRNewsWire
Sentiment: Neutral
Acquisition Adds Differentiated Investigational Molecule Designed to Treat Acute Myeloid Leukemia THOUSAND OAKS, Calif., Jan. 6, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced its acquisition of Dark Blue Therapeutics Ltd.
Read More
BMY vs AMGN: Which Biotech Stock Is More Resilient Now?
Published: December 30, 2025 by: Zacks Investment Research
Sentiment: Positive
AMGN edges out its rival with stronger growth estimates, a broad portfolio boost from Horizon, and momentum from key drugs like Repatha and Tezspire.
Read More
Can Amgen's MariTide Take on Leaders in the Obesity Space?
Published: December 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
AMGN's MariTide enters late-stage obesity trials with monthly dosing but faces rising competition as Eli Lilly and Novo Nordisk push oral GLP-1s.
Read More
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Published: December 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Can Amgen Sustain Its Rally In 2026
Published: December 26, 2025 by: Seeking Alpha
Sentiment: Positive
Amgen Inc. ends 2025 on a high note. Thanks to strong sales of Repatha and Imdelltra, it raised its full-year 2025 revenue guidance from $35-$36 billion to $35.8-$36.6 billion. So, sales of Repatha, a cholesterol-lowering medication, were $794 million in Q3, up 40% YoY.
Read More
Dogs of the Dow Beat the Market in 2025 — Here's the Smarter 4-Stock Play for 2026
Published: December 25, 2025 by: 24/7 Wall Street
Sentiment: Positive
Keeping things simple when investing is often best, which is why buying an index fund can be the optimal strategy.
Read More
Novo Nordisk vs. Amgen: Which Healthcare Stock Is the Smarter Choice?
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO and AMGN square off as GLP-1 leadership, pipeline depth, and diversification set up a compelling healthcare stock comparison.
Read More
5 Big Drug Stocks That May Continue to Outperform in 2026
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Five big drugmakers, including LLY and JNJ, are riding innovation, dealmaking and pipeline momentum that could help them keep outperforming in 2026.
Read More
Drug Sector on a High as 9 Drugmakers Strike Drug Pricing Deals
Published: December 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen and eight other pharma giants struck deals with the Trump administration to cut U.S. drug prices while gaining tariff relief and manufacturing incentives.
Read More
This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter
Published: December 19, 2025 by: CNBC Television
Sentiment: Neutral
CNBC's “Closing Bell Overtime” team discusses why the biotech recovery may continue into 2026 with Salveen Richter, lead U.S. biotech analyst at Goldman Sachs Research.
Read More
AMGEN TAKES ACTION WITH THE U.S. GOVERNMENT TO LOWER THE COST OF MEDICINES FOR AMERICAN PATIENTS
Published: December 19, 2025 by: PRNewsWire
Sentiment: Neutral
Underscores Long-Standing Commitment to Investing in Innovation and U.S. Manufacturing THOUSAND OAKS, Calif. , Dec. 19, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced it is taking action again with the U.S. government to lower medicine costs for American patients, while reinforcing Amgen's long-standing commitment to innovation.
Read More
Trump to announce new drug-pricing deals later today
Published: December 19, 2025 by: Market Watch
Sentiment: Positive
The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices.
Read More
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
Published: December 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
About Amgen Inc. (AMGN)
- IPO Date 1983-06-17
- Website https://www.amgen.com
- Industry Drug Manufacturers - General
- CEO Robert A. Bradway
- Employees 28000